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Abstract: Targeted delivery of drugs or other therapeutic agents through internal or external triggers
has been used to control and accelerate the release from liposomal carriers in a number of studies, but
relatively few utilize energy of therapeutic X-rays as a trigger. We have synthesized liposomes that
are triggered by ionizing radiation (RTLs) to release their therapeutic payload. These liposomes are
composed of natural egg phosphatidylethanolamine (PE), 1,2-distearoyl-sn-glycero-3-phosphocholine
(DSPC), cholesterol, and 1,2-disteroyl-sn-glycero-3-phosphoethanolamine-N-[methoxy (polyethylene
glycol)-2000] (DSPE-PEG-2000), and the mean size of the RTL was in the range of 114 to 133 nm, as
measured by nanoparticle tracking analysis (NTA). The trigger mechanism is the organic halogen,
chloral hydrate, which is known to generate free protons upon exposure to ionizing radiation. Once
protons are liberated, a drop in internal pH of the liposome promotes destabilization of the lipid
bilayer and escape of the liposomal contents. In proof of principle studies, we assessed RTL radiationrelease of fluorescent tracers upon exposure to a low pH extracellular environment or exposure to
X-ray irradiation. Biodistribution imaging before and after irradiation demonstrated a preferential
uptake and release of the liposomes and their cargo at the site of local tumor irradiation. Finally, a
potent metabolite of the commonly used chemotherapy irinotecan, SN-38, was loaded into RTL along
with near infrared (NIR) fluorescent dyes for imaging studies and measuring tumor cell cytotoxicity
alone or combined with radiation exposure, in vitro and in vivo. Fully loaded RTLs were found to
increase tumor cell killing with radiation in vitro and enhance tumor growth delay in vivo after three
IV injections combined with three, 5 Gy local tumor radiation exposures compared to either treatment
modality alone.
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Since the early 20th century, chemotherapy has improved in efficacy but is still mostly
a systemic cancer treatment, so patients’ entire bodies are exposed to toxic agents. Nonselective drug delivery leads to marginal accumulation in the tumor and dose-limiting
side effects that cause morbidity and can reduce treatment efficacy. Encapsulation of
chemotherapeutic drugs in a nanocarrier provides the possibility to increase drug levels
in tumors while diminishing side-effects and limiting the impact on efficacy. The main
reasons attributed to the limited efficacy of the classic drug delivery carriers are the low
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accumulation of the drug in tumors and the slow release from the carrier [1]. Tumortargeted delivery of chemotherapeutics to mitigate devastating side effects and while
retaining or improving drug efficacy compared to systemic delivery is challenging but
may allow for improved outcomes by using certain drugs to treat primary tumors while
using other agents, or reduced systemic dosages, to control systemic micrometastasis.
In this regard, many drugs have been incorporated into liposomes, and liposomal drug
delivery has shown improved cancer therapy efficacy in some studies [2–4]. The delivery
of some pH-sensitive drugs is still limited by the instability of the drug molecule itself in a
physiological environment or neutral pH [5].
Liposomes generally consist of one or more concentric phospholipid bilayer and an
aqueous interior chamber and have the capacity to encapsulate many different types of
water-soluble pharmaceuticals [5–7]. Liposomes have shown great potential in cancer
therapy and therapeutic agent delivery. Most recently, a majority of the successful mRNAbased COVID-19 vaccines were housed in lipid-based nanosize carriers [8,9]. While the
current non-triggered release approaches in liposomal drug delivery for the complicated
situation of a malignant tumor microenvironment exhibit reduced toxic profiles, some
preparations remain associated with systemic drug toxicities [10]. Because radiotherapy is
one of the most precise and non-invasive treatment modalities available to treat primary,
metastatic, or recurrent tumor volumes, liposomes containing chemotherapeutics that are
released by radiation exposure in a spatially and temporally controlled manner represent a
major opportunity to overcome toxic sequelae caused by systemic chemotherapy delivery.
Radiation-controlled drug release is expected to decrease chemotherapy side effects, increase drug efficacy against tumors, and combine with radiation-induced cell killing. These
benefits of radiation-triggered liposomes (RTLs) should allow patients to maintain a higher
quality of life along with a higher probability of effective treatment for instance inoperable
lung tumors [11].
SN-38, 7-ethyl-10-hydroxycamptothecin, is a highly biologically active metabolite
of CPT-11 (Irinotecan) and is a drug with much potential to be used in cancer therapy.
However, the clinical use of SN-38 is greatly limited because of its poor aqueous solubility
and instability at physiological pH [12,13]. Additionally, the current approaches to administration of SN-38 have resulted in side effects from nausea to more severe adverse
reactions such as severe diarrhea and neutropenia [14]. Therefore, SN-38 is a perfect fit in
some ways as a drug needing a tumor selective delivery mechanism so that it can avoid
normal tissue complications and kill tumor cells with high efficiency before losing activity.
Several drug-delivery carriers such as nanoparticles [15,16] liposomes [17] and polymeric
micelles [12,18,19] have been envisioned to solve this problem and increase the tumor
selective therapeutic effectiveness of SN-38. Among these, liposomes are the most popular,
extensively studied, and promising drug-delivery carrier for improving the efficacy of
SN-38 in cancer therapy. In fact, liposome irinotecan was recently approved for clinical
use [20] and liposomal SN-38 is currently in Phase II clinical trials [21]. However, the
formulations do not include a drug-release trigger.
After characterizing the behavior of our patented liposomal formulation under physiological conditions, we worked on a final approach to incorporate the highly toxic SN-38
(7-ethyl-10-hydroxy-camptothecin) into liposomes to improve its chemical stability and enhance its rapid delivery in target specific tissue with prolonged blood circulation time [22–26].
Our initial studies detailed here using the patented radiation-triggered RTL formulation
suggest that SN-38 or other drugs with potency against tumor cells, but poor bioavailability or stability can be effectively incorporated into a multi-modality treatment regimen.
The potential applications and therapy goals that might be positively impacted by the
RTL-mediated approach are discussed.
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2. Results
2.2.1.
Results
Characterization
2.1. Characterization
Nanoparticle tracking analysis (NTA) characterization of the RTL SN-38 loaded lip-
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Figure 1. Physical characterization of RTLs produced by extrusion. (A) Table of liposome characterFigure 1. Physical characterization of RTLs produced by extrusion. (A) Table of liposome characterisistics as measured by NTA at 25 °C. (B–C) Representative NTA plots the particle/mL vs. diameter
◦ C. (B–C) Representative NTA plots the particle/mL vs. diameter for
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(D) Cryo-TEM images of RTL liposomes containing PE:DSPC:Chol:DSPE-mPEG
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2.2. Payload Release from the Liposomes and Cell Viability
2.2. Payload Release from the Liposomes and Cell Viability
Figure 2 illustrates that we were able to induce release of liposome cargo in vitro by
Figure 2 illustrates that we were able to induce release of liposome cargo in vitro
using either and acidic environment (Figure 2A) or radiation exposure (Figure 2B) of lipby using either and acidic environment (Figure 2A) or radiation exposure (Figure 2B)
of liposomes loaded with carboxyfluorescein formulated with varying concentrations of
chloral hydrate (CH; 50 mM or 500 mM) and phosphate buffer (1 mM or 10 mM), and then
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Figure 2. Characterization of in vitro RTL release. (A) Demonstration of the pH dependent release
trigger as measured by carboxyfluorescein release from RTLs upon acidification with 70 µL of 0.1 M
HCl to a final pH of 5.7–5.9. (B) Carboxyfluorescein release from RTLs formulated with varying
concentrations of chloral hydrate (CH; 50 mM or 500 mM) and phosphate buffer (1 mM or 10 mM)
over 3 h of incubation alone or after 20 Gy irradiaton. Data representative of a single experiment.
(C) Cell viability after exposure to supernatant after incubation of SN-38 loaded RTLs at 37 ◦ C in
neutral or acidic pH. Liposomes were incubated in different pH buffers and then supernatant added
to the LLC tumor cells. (D) Clonogenic survival after incubating cells with SN-38 loaded liposomes
or SN-38 alone for 4 h before exposure to 2.5 or 5 Gy of radiation. The drug/liposomes were rinsed
off after radiation and replaced with fresh culture medium to allow for surviving cells to form
colonies. Average of 3 independent experiments with the bars showing the SD of the mean. Two-way
ANOVA with repeated measures for comparison of drug treatments plus radiation vs. radiation
alone (**** p < 0.0001).
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liposomes over time. Rapid tumor accumulation can be seen by the bright signal from the
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tumor region in the lateral images (Figure 3A) compared to baseline. Relative fluorescence
in the tumor region was quantified, corrected for background, and graphed in Figure 3B.
The rapid increase from time 0 to the first time point illustrates rapid tumor accumulation
of liposomes. Liposomes continued to accumulate in the tumor albeit at a slower rate for up
to 24 h after injection, when the experiment was terminated (Figure 3B). Figure 3C shows a
representative ex vivo image of the tissues at 24 h post injection and Figure 3D plots the
ex vivo fluorescent signal in tissues at 24 h post injection. After normalization for tissue
weight, the liver had the highest liposome accumulation followed by the tumor and then
the lungs. High liver accumulation is expected based on known liposome biodistribution
and lipid metabolism [11]. Additionally, by formulating our liposomes to 100–120 nm in
size, we were able to take advantage of the enhanced permeability and retention (EPR)
effect seen with tumors [31]. A low accumulation level in the lungs was also observed
with these liposomes (Figure 3C,D), which was encouraging as follow up studies will be
conducted in orthotopic lung tumor models.

Figure 3. Biodistribution of VivoTrack-labelled RTLs. (A) Representative IVIS images of Vivotrack
associated fluorescence over the course of 24 h post injection with VivoTrack + SN-38 loaded RTL
liposomes. (B) Average radiant efficiency in the tumor region of lateral images over 24 h. (C) Representative ex vivo IVIS image of VivoTrack associated fluorescence in vital organs and tumor at 24 h post
injection of VivoTrack + SN-38 loaded RTL liposomes. (D) Average radiant efficiency of vital organs
and tumor from a group of six identically treated animals. Data presented as mean ± SEM. One-way
ANOVA with Tukey post hoc for comparison of all tissues (* p < 0.05, ** p < 0.01, **** p < 0.0001).

VivoTrack fluorescence in this study only indicates liposome accumulation and does
not provide a measure of drug release from liposome. Thus, we observed that VivoTracklabeled RTL liposomes accumulate in the tumor and liver but did not assess whether they
have released their payload into these tissues.
2.4. In Vivo Radiation Release
ICG was loaded into liposomes at a self-quenching concentration (0.25 mg/mL). Thus,
fully intact liposomes displayed minimal fluorescence (Figure 4A). Based on biodistribution
data in Figure 3B, 4 h was determined to be the optimal time after liposome injection to
administer radiation. This timepoint would provide sufficient liposome accumulation in
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the tumor and allow for serial imaging post radiation. Figure 4B shows representative
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Figure 4. Radiation release of ICG-loaded RTLs. (A) Self-quenching ICG loaded liposomes. (B) Representative lateral IVIS images of ICG associated fluorescence 4 h post injection and immediately after
radiation. (C) Average radiant efficiency in the tumor region over the course of 24 h post radiation.
(D) Representative ex vivo IVIS imaging of ICG associated fluorescence in vital organs and tumor
at 24 h post radiation. (E) Average radiant efficiency of vital organs and tumor. Data presented as
mean ± SEM; n = 5–6. One-way ANOVA with Tukey post hoc for comparison of all tissues to tumor
for each group (* p < 0.05, ** p < 0.01).

Importantly, compared to tumor-targeted radiation (Figure 5A), when mice were
treated with whole-body radiation, a strong ICG fluorescent signal was detected in all tissues (Figure 5B). Compared to the ex vivo imaging in tumor targeted radiation (Figure 5C),
liposome release detected in whole-body radiation was significantly higher in the liver,
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2.5. Anti-Tumor Efficacy
2.5. Anti-Tumor Efficacy
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Figure 6. Tumor growth delay compared to untreated (control) LLC tumors grown in the rear limb
of C57 mice. Groups contained 5–10 individually treated mice and the data is plotted as the mean
with SD. SN-38 2 mg/kg or RTLs loaded with SN-38 corresponding to 2 mg/kg were injected IV on
days 0, 3 and 6. Radiation was administered to the tumor at a dose of 5 Gy on days 0, 3 and 6. In the
combined treatment group, RTLs (SN-38) were given IV at 2 mg/kg and 4 h after injection the tumor
was irradiated with 5 Gy. The average tumor volume at days 2–8 after the start of treatment in the
combined therapy group was significantly lower (p < 0.0002–0.04, Student’s t-test comparing average
fold change in tumor volume) than either monotherapy or control group. By day 10, the last day of
measurement, the tumors had all started to regrow at a similar rate since therapy had ended on day 6.

3. Discussion
The field of drug delivery and targeted release of therapeutics using nanomaterialbased vehicles has a long history, dating back at least 50 years to the early work of Gregoriadis [32,33]. While a wide variety of materials have been studied and investigated as drug
carriers, the liposome has garnered the most attention. Yet, the true control and design
of many lipid-based drug delivery systems remains less than optimal. Our goal in using
radiation therapy as a trigger for drug release was to exploit one of the most non-invasive,
potent, and precise therapies available to the oncologist. Radiation allows control and
precise tumor volume targeting while avoiding significant triggering in any normal tissues,
by virtue of the precision and accuracy of modern-day radiotherapy treatment planning.
There have been extensive efforts with triggering mechanisms using thermal therapy, with
some success [34]. However, in most cases the control of the trigger timing and tissue
volume of effect remains inexact due to the inherent nature of blood flow, thermal washout
from tissues and other vascular permeability issues. While these will also be factors in our
current platform, we surmise that the control and precision by which we can activate release
from liposomes taken into the interstitial space or into the tumor cells themselves will
facilitate a better therapeutic index that other approaches. By using conformal radiotherapy
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that does not depend on blood flow or conduction for dose deposition we add a new level
of control which warrants more development and testing.
This report summarizes the initial studies undertaken by the company/university
team at our institutions. Herein we have shown that our patented liposomes can be formulated to the size range and polydispersity index considered acceptable for drug delivery
applications by the FDA’s guidance for industries [27–30]. Moreover, we demonstrated
that the chemotherapy agent, SN-38 can be encapsulated in these liposomes, while maintaining the pH sensitivity that underlies the triggered release mechanism and cytotoxic
actions of the drug. This is evidenced by our cell viability and clonogenic assays that show
decreased survival with addition of just the supernatant after liposomes were exposed to
low pH or ionizing radiation. We interpret this to mean that robust quantities of active
SN-38 were released from the liposomes after triggering the release mechanism. It is this
delicate chemical interplay between pH, liposome stability, and drug action that makes our
formulation stand out from other liposome preparations.
The rapid tumor uptake and retention of our RTLs illustrated the enhanced permeability and retention effect [31], which is a universal pathophysiological phenomenon whereby
macromolecular compounds such as proteins, lipid vesicles and polymer-conjugated drugs
above 40 kDa progressively accumulate in the tumor vascularized area due to the “leakiness” of the newly formed blood vessels around the tumor. Properly sizing our liposomes
between 100–120 nm allowed us to take advantage of this phenomenon and achieve selective tumor delivery and retention. One aspect of our liposome platform that is also at work
is the pH sensitivity of our lipid composition. While we have initially found that radiation
induces a rapid and large enough change in pH to release the liposome cargo, we also
recognize that the low pH of the tumor microenvironment itself may be inducing greater
release of the drug/tracer molecules than in other tissues that maintain a more neutral pH.
This can be seen in the data shown in Figure 4D,E where even the tumor tissue that was not
irradiated was found to have higher levels of the loaded ICG than in most other tissues. We
interpret this to reflect the induced release of cargo by the liposomes that were taken up in
the acidic tumor microenvironment. It is this mechanism that most pH sensitive liposome
formulations intend to harness to promote tumor selective drug delivery. However, in the
absence of a release trigger these pH sensitive liposomes release their payload slowly, which
may limit maximum drug concentrations at the tumor, whereas the release from our RTLs
was found to be further enhanced and more rapid once local radiation was administered.
These combined release factors are likely what led to the increased tumor response found
in the growth delay study shown in Figure 6. While the rapid growing tumor model used
in our proof of principle studies here did not allow for a lengthier course of liposome and
radiation treatments, an indication of treatment synergism was observed over the course of
six days and three combined treatments where the tumor growth was clearly inhibited or
at the least altered compared to the single treatment modalities or tumors that were left untreated. Compared to the single radiation dose (6 Gy) used in the radiation release studies,
we modeled our anti-tumor efficacy treatment as a fractionated radiation regimen to assess
the efficacy of multiple rounds of treatment with drug containing liposomes. This radiation
dose (5 Gy) was chosen to limit the total radiation dose (15 Gy) and still provide sufficient
triggered liposomal release. The tumor volume was maintained at a significantly lower size
for a week (days 2–8 after treatment) which suggests that had we continued treatment, as
would be the case in a clinical version of this treatment modality, we could have achieved
far greater tumor control. These are all indications that warrant further expanded studies to
prepare our liposomal platform for translation, either with the current drug (SN-38, nearing
FDA approval) or with other already approved agents that could be easily brought into
currently accepted chemoradiation regimens for a number of disease sites.
Additionally, our RTLs include PEGylated lipids and are formulated to be “stealth”
liposomes, which evade uptake and breakdown by macrophages and Kupffer cells in the
liver [35]. While our RTLs accumulated in tissues outside the tumor region including the
liver; there appeared to be minimal release or retention of SN-38 without the radiation
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trigger. These findings suggest that our liposomes may be able to deliver tumor-targeted
cancer therapy with minimal exposure to other tissues. All in all, we have provided proof
of concept that our drug delivery platform, RTLs, can provide tumor-targeted drug release
when combined with radiation, and thus has the potential to enhance tumor control while
reducing off-target toxicities. These findings raise the possibility of encapsulating a variety
of chemotherapeutic agents to improve their bioavailability, stability, and tumor uptake,
while limiting exposure to other tissues. However, it is possible that the protocol and buffering agents may need to be modified to successfully encapsulate other chemotherapeutics
based on their unique chemistries. Future studies will focus on pharmacokinetics and more
extensive dose response studies to further evaluate tissue drug concentration, elimination
half-life, anti-tumor effectiveness, and off-target toxicities.
4. Materials and Methods
4.1. Chemicals
1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-distearoyl-sn-glycero-3phosphoethanolamine-N-[methoxy (polyethylene glycol)-2000] ammonium salt (DSPE-mPEG2000 or 18:0PEG2000PE), and cholesterol were bought from Avanti Polar Lipids LLC
(Alabaster, AL, USA), L-α-Phosphatidylethanolamine (PE) from egg yolk was purchased as
a lyophilized powder from Sigma Aldrich (St. Louis, MO, USA). All lipids purchased were
used without further purification. SN-38 in powder was purchased from Fisher Scientific
(Waltham, MA, USA) and its stock solution was prepared in dimethyl sulfoxide (DMSO;
10 mg/mL). Reagents such as methanol and chloroform were purchased from Fisher Scientific and used as provided. Sephadex G-75 and carboxyfluorescein were purchased
from Sigma Aldrich (St. Louis, MO, USA). Indocyanine green (ICG) was purchased from
Fisher Scientific (Waltham, MA, USA). Vivotrack 680 was purchased from PerkinElmer
(Hopkinton, MA, USA).
4.2. Animals
For biodistribution and tumor radiation release imaging studies, 8–12-week-old female
C57BL/6J albino mice were purchased from Jackson Laboratories (Bar Harbor, ME, USA).
Mice were inoculated subcutaneously in the flank with 1 × 106 Lewis lung carcinoma
cells (LLCs; ATCC, Manassas, VA, USA). For tumor efficacy study, 8–12-week-old male
C57BL/6J mice were purchased from Jackson Laboratories (Bar Harbor, ME, USA). Mice
were inoculated subcutaneously in the rear limb with 1 × 106 Lewis Lung Carcinoma (LLC)
cells. Experiments were started 7–10 days after tumor inoculation when the tumors reached
a volume of 250 mm3 . All procedures were carried out in accordance with the Guide for
the Care and Use of Laboratory Animals as adopted and promulgated by the U.S. National
Institutes of Health and approved in animal use protocols at Charles River Laboratories
and by the Institutional Animal Care and Use Committee at the University of Arkansas for
Medical Sciences.
4.3. Liposomes Preparation
4.3.1. Preparation of Spherical Lipid Bilayers
The lipid components used to prepare lipid bilayers composed of PE, DSPC, Cholesterol, and DSPE-mPEG (Molar ratio 1:0.5:0.5:0.075) and prepared by the extrusion method
as described previously [21]. Briefly, lipids with a combined mass of 20.5 mg were dissolved in 1.3 mL of chloroform in a glass vial. The homogeneous mixture of lipids was then
transferred to a 50 mL round bottom centrifuge tube using a Hamilton syringe. A dried
thin film lipid bilayer was formed in the tube by rotatory evaporation of solvent under
vacuum at 50 ◦ C at a constant speed of 100 rpm for 2 h.
4.3.2. SN-38 Loaded Liposome Preparation
The tube was warmed at 70 ◦ C for 30 min and the lipid bilayer was disrupted by
adding 27 mm glass beads to the tube and shaking continuously. The thin film lipid
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bilayer was hydrated with 1.3 mL of saline solution (pH 7.2–7.4) containing 50 mM Chloral
hydrate, 5 mM phosphate, and 1 mg/mL SN-38. Approximately 120 nm size SN-38-loaded
liposome was obtained by passing the suspension through a mini-extruder (Avanti Polar
Lipids) using polycarbonate filter membranes with pore sizes 400 nm, which was further
downsized by a 100 nm pore size filter membrane. The unencapsulated SN-38 was removed
using a Sephadex G-75 column equilibrated with 0.9% saline solution (pH 7.2).
4.3.3. Carboxyfluorescein- and ICG- Loaded Liposome Preparation
Carboxyfluorescein- and ICG (indocyanine green)-loaded liposomes were prepared
in a similar way as described above for the fluoresence release and in vivo animal studies.
Carboxyfluorescein and ICG were dissolved in PBS adjusting pH to 7.4 using 0.1 M NaOH
or 0.1 M HCl. Carboxyfluorescein was loaded into the liposome at the concentration of
30 mM whereas ICG was at 0.25 mg/mL. The stock solutions of these fluorescent dyes
were prepared in the PBS and added to the loading solution at desired concentration
prior to the extrusion of lipids suspension. The excess carboxyfluorescein or ICG from the
liposomes were removed using a Sephadex G-75 column equilibrated with 0.9% saline
solution (pH 7.2). Empty liposomes were prepared in a similar way as described above
except for the addition of SN-38, carboxyfluorescein or ICG into the loaded solution. All
the liposomes prepared were stored at 4 ◦ C for future use.
4.3.4. Liposome Labeling with Vivo-Track 680
NIR fluorescent VivoTrack dyes were used for in vivo imaging. In this paper, liposomes labeling with Vivotrack-680 was performed as follows. First, the VivoTrack-680
solution in PBS was prepared according to the Technical Data Sheet provided by the
PerkinElmer Company (Hopkinton, MA, USA). In brief, 0.2 mg of VivoTrack-680 powder
was dissolved in warm sterile 1.3 mL of 1× PBS by gentle swirling and vortexing to yield
2.0 mL of the labeling agent (0.1 mg/mL). After ensuring the solid was fully dissolved
in the PBS solution, it was stored at 4 ◦ C protected from the light with aluminum foil for
labeling with liposomes. Next 1 mL of the prepared liposome loaded with SN-38 was
ultra-centrifuged at 137,000× g for 30 min, the supernatant was discarded, and 1 mL of the
VivoTrack-680 solution was added to liposome pellet. The solution was mixed immediately
by vortexing and incubated for 15 min at room temperature protecting from the light. After
incubation, the solution was washed 3 times by ultracentrifuge at 13,700× g for 30 min
each time with 1 mL of PBS to remove the excess of labelling agent. The final liposome
pellet with VivoTrack-680 labeling agent was resuspended in 1 mL PBS.
4.4. Characterization
4.4.1. NTA (Nanoparticle Tracking Analysis)
The hydrodynamic diameter, particle size distribution/mL, and particle concentration/mL of liposomes were determined using Nanoparticles Tracking Analysis (NTA;
Particle Metrix (Ammersee, Germany), ZetaVIEW S/N 18-379, software ZetaView 8.04.02
SP2, Camera 0.713 µm/px). Samples were diluted in a ratio of 1:100, 1:1000, 1:10,000,
1:100,000, 1:100,000 in PBS and ran in the instrument. One mL of the diluted sample was
loaded into the 1 mL plastic syringe, injected into the instrument, and the measurements
carried out upon illumination by the laser light (635 nm).
4.4.2. Cryo-Electron Microscopy (Cryo-EM)
The surface morphology, shape, and size of the liposome were frozen using a Leica
EMPACT2/AFS2 (Wetzlar, Germany) and sliced by a Leica Ultracut 7 Microtome (Wetzlar,
Germany) with Cryo-attachment. Samples were then observed using a FEI Tecnai F20
200 keV Transmission Electron Microscope (TEM) in the University of Arkansas for Medical
Sciences Digital Microscopy Core.
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4.4.3. Release of Carboxyfluorescein
Liposomes were loaded with 50 mM carboxyfluorescein in saline solution containing
50 mM or 500 mM Chloral hydrate alone or with 1 or 10 mM phosphate. RTLs were then
incubated at 37 ◦ C and a portion was irradiated with 20 Gy at the 0 h. At 1, 2, 3 h post
irradiation a sample was taken out and centrifuged at 137,000× g for 30 min and transferred
to 96 well plate, where the fluorescence signal was measured at excitation/emission range
of 490/517.
4.5. In Vitro and In Vivo Efficacy
4.5.1. Cell Viability
SN-38 loaded liposomes were incubated at 37 ◦ C in neutral and acidic saline solution
(pH adjusted to pH 7 and 5 using 10 mM Citrate buffer) for 0, 2, and 4 h, and then
centrifuged at 137,000× g for 30 min. 5 µL of the supernatant was added to 100 µL of
medium in 96 well plate containing LLC tumor cells. As a control for cell killing effect of
full release of SN-38, cells were treated with supernatant from liposomes treated with 0.1%
Triton X-100. Cell viability was assessed using CCK8 method and values were normalized
to the relevant untreated controls.
4.5.2. Clonogenic Assay
H460 human lung tumor cells were treated with free SN-38 or SN-38 loaded liposomes
for 4 h and then subjected to graded radiation of 2.5 and 5 Gy. Fifteen minutes after
radiation media was removed and replaced with fresh media. Cells were incubated for
5–7 days to form colonies and then stained with crystal violet blue, colonies were counted,
and normalized to the untreated controls of each treatment to evaluate the survival.
4.5.3. Biodistribution
Eight- to twelve-week-old female C57BL/6J albino mice were inoculated subcutaneously in the flank with 1 × 106 LLC cells. Tumors were allowed to grow for 7–10 days
until they reached a target size of 250 mm3 . A baseline whole-body ventral and lateral
image was captured using an IVIS imager (PerkinElmer, Hoptkin, MA, USA). Then, animals were administered VivoTrack–labeled, SN-38-loaded RTL liposomes (100 µL) and
whole-body lateral images were collected at 1, 2, 4, 6, 8, and 24 h post injection. Immediately following the 24 h image vital organs (liver, whole lung, kidneys) and tumor were
collected and imaged ex vivo. Vivotrack associated fluorescence in the tumor region of
the whole-body images was analyzed for each time point and compared to baseline to
determine time to optimal tumor accumulation for the subsequent radiation release study.
Vivotrack associated fluorescence in vital organs and tumor were used to determine relative
RTL biodistribution.
4.5.4. Radiation Release in the Tumor
Eight- to twelve-week-old female C57BL/6J albino mice were inoculated subcutaneously in the flank with 1 × 106 LLC cells. Tumors were allowed to grow for 7–10 days
until they reached a target size of 250 mm3 . A baseline whole-body lateral image was
captured using an IVIS imager. Then, animals were randomized into 4 groups and were
administered either, ICG-loaded RTL liposomes (100 µL), ICG loaded RTL liposomes
(100 µL) +6 Gy tumor targeted radiation, ICG loaded RTL liposomes (100 µL) +12 Gy
tumor targeted radiation, or ICG loaded RTL liposomes + 6 Gy whole-body radiation.
Animals were injected intravenously with RTL liposomes first and then irradiated 4 h after
injection. Whole-body lateral images were collected at 0.5, 2, 4, 6, and 24 h post irradiation.
Immediately following the 24 h image vital organs (liver, whole lung, kidneys) and tumor
were collected and imaged ex vivo. ICG associated fluorescence in the tumor region of
the whole-body images was analyzed for each timepoint and compared to baseline to
determine liposome release. ICG associated fluorescence in vital organs and tumor were
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used to determine relative liposomal release. Irradiation was performed using 225 keV
beam generated by a Faxitron MultiRad 225 X-ray system (Hologic, Tuscon, AZ, USA).
4.5.5. Anti-Tumor efficacy
Eight- to twelve-week-old male C57BL/6J mice were inoculated subcutaneously in
the rear limb with 1 × 106 Lewis Lung Carcinoma cells. Tumors were allowed to grow
for 7–10 days after tumor inoculation until the tumors reached a target of 250 mm3 . Then,
animals were randomized into 5 groups and were administered saline, free SN-38, SN-38
loaded RTL liposomes, 5 Gy radiation, or SN-38 loaded RTL liposomes + 5 Gy radiation.
Animals were dosed every 3 days for a total of 3 cycles. For animals receiving combination
therapy, SN-38 loaded liposomes were injected first and then tumors were irradiated 4 h
post injection. Tumors were measured with calipers on Day 1 and then every 3 days.
Irradiation was performed using 320 keV beam generated by XRad320 (Precision X-Ray,
Branford, CT, USA).
5. Patents
The liposomes studied in this manuscript are protected by a United States patent US
9,849,087 B2 and European Patent EP2776013A1.
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